CPT code 90385 denotes Rho(D) (Rhesus D) immunoglobulin, a plasma‑derived passive immunization product used to prevent maternal alloimmunization and hemolytic disease of the newborn. Nationally, this code captures a critical obstetric prophylactic intervention administered when Rh‑negative individuals are exposed to Rh‑positive blood, such as after delivery, miscarriage, certain prenatal procedures, or trauma. Its use supports neonatal safety and reduces severe morbidity from hemolytic disease.

Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for 90385, typical sites where the product is administered, and which payers commonly reimburse the service. The publication summarizes reimbursement benchmarks and coverage patterns, highlights common billing practice considerations associated with administration in obstetric and outpatient infusion settings, and notes areas where policy language affects access and billing (e.g., coverage criteria tied to obstetric events).

This summary is intended for clinicians, billing professionals, and policy analysts seeking a national perspective on clinical use, payer coverage, and the operational settings tied to CPT code 90385. Data not available in the input are identified where applicable.